Flow cell devices, cartridges, and systems are described that provide reduced manufacturing complexity, lowered consumable costs, and flexible system throughput for nucleic acid sequencing and other chemical or biological analysis applications. The flow cell device can include a capillary flow cell device or a microfluidic flow cell device.

A method for diagnosing COVID-19 infection. The method includes drawing a blood sample from a person suspected to be infected with COVID-19 virus, separating a blood serum sample from the blood sample by centrifuging the blood sample, recording an electrochemical impedance spectroscopy (EIS) associated with the blood serum sample, calculating a charge transfer resistance (R.sub.CT) of the recorded EIS by measuring a diameter of a semicircular curved part of the recorded EIS, and detecting a COVID-19 infection of the person based on the calculated R.sub.CT if the calculated R.sub.CT is equal to or more than a threshold value.

Systems and processes to screen for SARS-CoV-2, which includes a process that uses an alternative antibody for ELISA. The alternative antibody is an alternative to a mouse antibody, thereby expanding the ability to test for COVID-19 using non-human antibodies.

A photonic biosensor including a biological probe disposed on a mid-infrared-transparent waveguide can be used to detect biological analytes in biological samples, using specific binding of the analyte to the probe in conjunction with absorption spectroscopy. In various embodiments, the biosensor is used for molecular diagnostics, e.g., to detect oligonucleotides or proteins associated with a coronavirus.

This disclosure describes portable bio-nano-chip assays, methods and compositions for diagnosing and assessing pathogen-mediated diseases or infections at point-of-care using biological samples. The assays, methods and compositions provide in a more convenient, less expensive, and less time-consuming sampling and analysis.

Devices and methods incorporate mucolytic agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters one or more lysis agents and/or mucolytic agents. The mucolytic agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the mucolytic agent is localized between the sample application zone and the conjugate zone. In embodiments with a sample compressor, one or more mucolytic agents may be pre-loaded and dried on the sample compressor, the sample collector, in various locations on the test strip, or in the running buffer.

Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.

Test devices are provided for determining the presence of a first ligand in a sample. In some embodiments depletion conjugates are used to deplete the ligands different from but related to the first ligands from the sample.

A system comprised of an apparatus and a test device is described. The test device and the apparatus are designed to interact to determine the presence or absence of an analyte of interest in a sample placed on the test device.

Apparatuses and methods of optically analyzing fluid within a pipette are described herein. In an embodiment, an optical reader subassembly includes a housing including an internal area, a container configured to hold a fluid sample at a sample position in a light tight manner within the internal area of the housing, a light source configured to project light onto the fluid sample within the container, and an optical sensor configured to move between different sensor positions while the fluid sample remains stationary at the sample position, the different sensor positions including at least two of: (i) a first sensor position for taking a luminescence reading of the fluid sample; (ii) a second sensor position for taking a dark current or other background measurement; and (iii) a third sensor position for taking a fluorescence reading of the fluid sample.